LY2409881 is primarily investigated for its potential in cancer treatment. It functions as an inhibitor of the IKK2 enzyme, which plays a crucial role in the NF-kappaB signaling pathway. This pathway is often dysregulated in various cancers, contributing to tumor growth, survival, and resistance to therapy. By inhibiting IKK2, LY2409881 can suppress the NF-kappaB pathway, potentially reducing tumor progression and enhancing the effectiveness of other cancer therapies. Research is ongoing to explore its use in combination with chemotherapy or radiation to improve outcomes in cancer patients. Additionally, its role in modulating inflammation makes it a candidate for studying inflammatory diseases linked to NF-kappaB activation.